Concurrent paclitaxel and radiation therapy for solid tumors

H. Choy, W. Akerley, M. Glantz, H. Safran, S. Graziano, C. Chung

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Background: Combination radiation and chemotherapy has an intuitive appeal for improving cancer treatment. Experimental results suggest that paclitaxel plus radiation might produce additive or synergistic effects. Methods: A series of phase I and II trials to test tolerance and begin to evaluate effectiveness were performed on patients with non-small cell lung cancer, high-grade astrocytic brain tumors, and pancreatic and gastric cancers. Results: Tolerance of the combined drug and radiation programs was generally good. Esophagitis was dose-limiting for the intrathoracic tumors. Hematologic toxicity was mild, but peripheral neuritis and cutaneous reactions were common. Conclusions: These trials show that paclitaxel plus concurrent radiation is feasible at the dose levels and schedules tested. Antitumor responses have been observed.

Original languageEnglish (US)
Pages (from-to)310-318
Number of pages9
JournalCancer Control
Volume3
Issue number4
DOIs
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Concurrent paclitaxel and radiation therapy for solid tumors'. Together they form a unique fingerprint.

  • Cite this

    Choy, H., Akerley, W., Glantz, M., Safran, H., Graziano, S., & Chung, C. (1996). Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control, 3(4), 310-318. https://doi.org/10.1177/107327489600300402